Enhanced blood pressure sensitivity to DOCA-salt treatment in endothelin ET(B) receptor-deficient rats

Br J Pharmacol. 2000 Mar;129(6):1060-2. doi: 10.1038/sj.bjp.0703157.

Abstract

The role of endothelin ET(B) receptor-mediated action in the development and maintenance of deoxycorticosterone acetate (DOCA)-salt-induced hypertension was evaluated using the spotting-lethal (sl) rat which carries a naturally occurring deletion in the ET(B) receptor gene. Homozygous (sl/sl) rats treated with DOCA-salt for 1 week exhibited an earlier onset of hypertension than heterozygous (sl/+) and wild-type (+/+) rats (systolic blood pressure, SBP; 156.7+/-3.4 versus 128.8+/-5.3 and 132.9+/-3.7 mmHg, respectively). Four weeks after the start of DOCA-salt treatment, homozygous rats developed marked hypertension, with a SBP of 206. 0+/-4.5 mmHg, compared with 184.8+/-10.7 mmHg in heterozygous and 164.3+/-4.8 mmHg in wild-type rats. Cardiovascular hypertrophy and renal dysfunction observed after 4-weeks treatment with DOCA-salt were more severe in homozygous rats, compared to wild-type and heterozygous animals. These evidences support strongly the view that ET(B) receptor-mediated actions are a protective factor in the pathogenesis of DOCA-salt-induced hypertension.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Pressure / drug effects*
  • Body Weight / drug effects
  • Creatinine / blood
  • Creatinine / urine
  • Desoxycorticosterone / pharmacology*
  • Dopamine beta-Hydroxylase / deficiency
  • Dopamine beta-Hydroxylase / genetics
  • Kidney Function Tests
  • Male
  • Nephrectomy
  • Organ Size / drug effects
  • Rats
  • Receptor, Endothelin B
  • Receptors, Endothelin / deficiency*
  • Receptors, Endothelin / genetics

Substances

  • Receptor, Endothelin B
  • Receptors, Endothelin
  • Desoxycorticosterone
  • Creatinine
  • Dopamine beta-Hydroxylase